Latest Global Distribution News

Aquirian Limited has bolstered its growth trajectory with a $20 million Mt Ida contract and significant advancements in its patented Collar Keeper® system, alongside commissioning its Wubin facility.

Audeara Limited has initiated three new white-label Auracast™ programs with Clinico Inc., alongside launching its BT-03 Audio Broadcaster in Australia, marking a significant step in scaling its audio technology globally.

Advanced Braking Technology Ltd reported a robust 27.2% revenue increase and a 61.6% rise in net profit for H1 2026, driven by strong international sales and progress in autonomous braking technology.

Tetratherix Limited reported a $4.6 million statutory loss for the first half of FY26, driven by increased R&D and manufacturing investments, while making significant progress in clinical trials and securing key global partnerships.

Orthocell Limited has reported a record half-year revenue of $6.2 million, driven by accelerating sales of its regenerative medicine products and expanding global footprint. The company’s US commercial launch of Remplir™ is gaining momentum alongside new market entries in Canada, Hong Kong, and Europe.

EZZ Life Science Holdings has secured a four-year exclusive global distribution agreement with Aumake Limited, committing to at least A$10 million in purchases. This partnership aims to accelerate EZZ’s international reach while preserving brand control.

Aumake Limited has secured a four-year exclusive global distribution agreement with EZZ Life Sciences, targeting $10 million in sales and expanding its footprint in high-margin nutraceuticals.

Nanoveu Limited has raised A$7.5 million through a strategic placement to accelerate the commercial rollout of its cutting-edge EMASS ECS-DoT semiconductor technology, including a rapid 16nm chip tape-out and live drone validation.

Orthocell Limited has reported a record $3.2 million revenue for the December 2025 quarter, marking its seventh consecutive quarter of growth, fuelled by expanding sales of its nerve repair product Remplir in the US and other international markets.

Tetratherix has inked a global exclusive distribution agreement with healthcare giant Henry Schein, paving the way for its first bone regeneration product, Tegenix, to enter major markets in 2026. Concurrently, the company has begun building an advanced manufacturing facility to meet expected global demand.

Orthocell has increased its investment in Marine Biomedical to 11.7%, securing exclusive distribution rights to the innovative PearlBone™ technology as it nears FDA approval.

Nova Eye Medical has reported a record US$6.1 million in sales for the December 2025 quarter, driven by strong US demand and a 24% annual growth rate that outpaces the industry.